
Rocket Lab remains a buy despite a nearly one-year Neutron rocket delay and lowered revenue forecast.
Rocket Lab Corporation (RKLB) is still recommended as a buy despite an expected delay of nearly one year for its Neutron rocket. The delay reduces 2030 revenue estimates by $320 million and lowers the fair value per share by 14% to $86. However, secu...





